Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

@article{Biswal2020EfficacyOA,
  title={Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial},
  author={Shibadas Biswal and C. Borja-Tabora and Luis Martinez Vargas and Derek Wallace},
  journal={The Lancet},
  year={2020},
  volume={395},
  pages={1423-1433}
}
  • Shibadas Biswal, C. Borja-Tabora, +1 author Derek Wallace
  • Published 2020
  • Medicine
  • The Lancet
  • BACKGROUND A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years. METHODS We present data up to 18 months post-vaccination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and… CONTINUE READING
    23 Citations
    The impact of serotype cross-protection on vaccine trials: DENVax as a case study
    • Highly Influenced
    • PDF
    The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study
    • Highly Influenced
    • PDF
    Dengue vaccine development by the year 2020: challenges and prospects
    Dengue virus 4: the ‘black sheep’ of the family?
    • L. Lazo
    • Biology, Medicine
    • Expert review of vaccines
    • 2020
    Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?
    • 1
    • Highly Influenced
    • PDF
    Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
    • 1
    • PDF

    References

    SHOWING 1-10 OF 31 REFERENCES
    Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
    • 63